GI CANCERS

The FDA has deferred action on the biologics license application for tislelizumab as a second-line treatment in esophageal squamous cell carcinoma.

In the phase 2 MOUNTAINEER study, the investigational combination of tucatinib and trastuzumab achieved durable response in patients with metastatic colorectal cancer.

In the phase 3 TOPAZ-1 trial, the addition of durvalumab to standard-of-care chemotherapy achieved a statistically significant improvement in overall survival compared chemotherapy alone, meeting the study's primary end point.

Cathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.

In the RATIONALE 306 clinical trial, the combination of tislelizumab and chemotherapy achieved a 34% reduction in the risk of death in patients with unresectable, locally advanced, or metastatic esophageal squamous cell carcinoma with either high or low PD-L1 expression.

PT886 was granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

Botensilimab and balstilimab use in patients with microsatellite stable colorectal cancer showed strong durability and superior efficacy, according to expanded data from the phase 1b C-800 study

In an interview with Targeted Oncology, Charles J. Schneider, MD, FACP, provided an overview of the treatment landscape for anal carcinoma, and ongoing research.

Tanios S. Bekaii-Saab, MD, FACP, discusses the unmet needs that are hoped to be filled by the phase 1/2 KRYSTAL-1 study.

Orphan drug designation has been granted to QXL138AM for the treatment of patients with pancreatic cancers.

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor in patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

Should the primary tumor, if asymptomatic, be resected in patients with colon cancer with synchronous unresectable metastases? Study results hint that the answer is no.

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

Chemotherapy may be avoidable for patients with stage II colon cancer, and circulating tumor DNA has demonstrated the ability to detect which patients, according to phase 2 study results.

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct

Charles J. Schneider, MD, FACP, discusses the overall prognosis of patients with anal carcinoma.

The FDA has granted approval to nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology, Ping Chi, discussed the novel strategy of combining KIT and MEK inhibition to treat patients with GIST treated in the frontline setting.

Although there was no significant overall survival benefit shown with pembrolizumab in the KEYNOTE-177 study, response and safety findings still support its use as a frontline option for patients with microsatellite instability high and mismatch repair deficient metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.

The FDA has granted priority review to a supplemental biologics license application for durvalumab as treatment of patients with locally advanced or metastatic biliary tract cancer.

The FDA has granted orphan drug designation to AB001 for the treatment of patients with pancreatic cancer and acute myeloid leukemia.